Stable heterodimeric antibody design with mutations in the Fc domain
US10457742B2 · kind B2 · utility
3Cited by
31References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 20, 2017 |
| Grant date | Oct 29, 2019 |
| Priority date | — |
| Expiry date | Mar 24, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.